<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36423831</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>209</Volume><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier.</ArticleTitle><Pagination><StartPage>105475</StartPage><MedlinePgn>105475</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2022.105475</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(22)00244-3</ELocationID><Abstract><AbstractText>SARS-CoV-2 is the causative agent of the immune response-driven disease COVID-19 for which new antiviral and anti-inflammatory treatments are urgently needed to reduce recovery time, risk of death and long COVID development. Here, we demonstrate that the immunoregulatory kinase p38 MAPK is activated during viral entry, mediated by the viral spike protein, and drives the harmful virus-induced inflammatory responses. Using primary human lung explants and lung epithelial organoids, we demonstrate that targeting p38 signal transduction with the selective and clinically pre-evaluated inhibitors PH-797804 and VX-702 markedly reduced the expression of the pro-inflammatory cytokines IL6, CXCL8, CXCL10 and TNF-&#x3b1; during infection, while viral replication and the interferon-mediated antiviral response of the lung epithelial barrier were largely maintained. Furthermore, our results reveal a high level of drug synergism of both p38 inhibitors in co-treatments with the nucleoside analogs Remdesivir and Molnupiravir to suppress viral replication of the SARS-CoV-2 variants of concern, revealing an exciting and novel mode of synergistic action of p38 inhibition. These results open new avenues for the improvement of the current treatment strategies for COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faist</LastName><ForeName>Aileen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany; CiM-IMPRS, University of Muenster, Cells in Motion-International Max Planck Research School - Molecular Biomedicine, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schloer</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Group "Regulatory Mechanisms of Inflammation", Institute of Medical Biochemistry, Center for Molecular Biology of Inflammation, Germany; "Cells in Motion" Interfaculty Center, University of Muenster, Muenster, Germany; Leibniz Institute for Experimental Virology, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecate-Zambrano</LastName><ForeName>Angeles</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany; Interdisciplinary Centre for Clinical Research, Medical Faculty, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janowski</LastName><ForeName>Josua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boergeling</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany; Interdisciplinary Centre for Clinical Research, Medical Faculty, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>Beate C G</ForeName><Initials>BCG</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sriram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany; EvoPAD Research Training Group 2220, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toebben</LastName><ForeName>Leonie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schughart</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infection Genetics, Helmholtz Centre for Infection Research, Braunschweig, Germany; University of Veterinary Medicine Hannover, Hannover, Germany; Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumgardt</LastName><ForeName>Morris</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for Infectious Diseases and Respiratory Medicine, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of the Freie Universit&#xe4;t Berlin, Humboldt-University Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessler</LastName><ForeName>Mirjana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for Infectious Diseases and Respiratory Medicine, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of the Freie Universit&#xe4;t Berlin, Humboldt-University Berlin and Berlin Institute of Health, Berlin, Germany; Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoenzke</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department for Infectious Diseases and Respiratory Medicine, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of the Freie Universit&#xe4;t Berlin, Humboldt-University Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hocke</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department for Infectious Diseases and Respiratory Medicine, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of the Freie Universit&#xe4;t Berlin, Humboldt-University Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trautmann</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, Muenster, Germany; Gerhard-Domagk-Institute of Pathology, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, Muenster, Germany; Gerhard-Domagk-Institute of Pathology, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular Immunology, University Hospital Bonn, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rescher</LastName><ForeName>Ursula</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Research Group "Regulatory Mechanisms of Inflammation", Institute of Medical Biochemistry, Center for Molecular Biology of Inflammation, Germany; "Cells in Motion" Interfaculty Center, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christersson</LastName><ForeName>Anmari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuehn</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellmann</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Hygiene, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolff</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Unit 17 "Influenza and Other Respiratory Viruses", Robert-Koch-Institute, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuempers</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine D, Division of General Internal and Emergency Medicine, Nephrology, and Rheumatology, University Hospital Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovas</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine D, Division of General Internal and Emergency Medicine, Nephrology, and Rheumatology, University Hospital Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiewrodt</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine A, University Hospital Muenster, Muenster, Germany; Department of Respiratory Medicine and Thoracic Oncology, Foundation Mathias Spital, Rheine and Ibbenbueren, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiebe</LastName><ForeName>Karsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, University Hospital Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barth</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gerhard-Domagk-Institute of Pathology, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany; "Cells in Motion" Interfaculty Center, University of Muenster, Muenster, Germany; Interdisciplinary Centre for Clinical Research, Medical Faculty, University of Muenster, Muenster, Germany; EvoPAD Research Training Group 2220, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunotte</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Virology (IVM), University Hospital Muenster, University of Muenster, Muenster, Germany; Interdisciplinary Centre for Clinical Research, Medical Faculty, University of Muenster, Muenster, Germany. Electronic address: brunotte@uni-muenster.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI100625</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="Y">p38 Mitogen-Activated Protein Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral response</Keyword><Keyword MajorTopicYN="N">Immunomodulation</Keyword><Keyword MajorTopicYN="N">Molnupiravir</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">p38 MAPK</Keyword></KeywordList><CoiStatement>Declaration of competing interest LB, SL, SS, AF and UR submitted a patent application for the use of p38 inhibitors with nucleoside analogs for the treatment of COVID-19 (EU patent nr. 21183887.5). SL is a cofounder and member of the advisory board of Atriva Therapeutics GmbH, Tuebingen, Germany.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36423831</ArticleId><ArticleId IdType="pmc">PMC9677559</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2022.105475</ArticleId><ArticleId IdType="pii">S0166-3542(22)00244-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed M., et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine. 2020;26 doi: 10.1016/j.eclinm.2020.100527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100527</ArticleId><ArticleId IdType="pmc">PMC7473262</ArticleId><ArticleId IdType="pubmed">32923992</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano T., et al. X-linked recessive TLR7 deficiency in &#x223c;1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 2021;6 doi: 10.1126/sciimmunol.abl4348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4348</ArticleId><ArticleId IdType="pmc">PMC8532080</ArticleId><ArticleId IdType="pubmed">34413140</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370 doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., et al. Remdesivir for the treatment of covid-19 - final report. N. Engl. J. Med. 2020;383:1813&#x2013;1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful apporach to multiple testing. J. Roy. Stat. Soc. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Berenbaum M.C. What is synergy? Pharmacol. Rev. 1989;41:93&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">2692037</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Rentsch M., Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS One. 2011;6 doi: 10.1371/journal.pone.0025858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025858</ArticleId><ArticleId IdType="pmc">PMC3187809</ArticleId><ArticleId IdType="pubmed">21998709</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036&#x2013;1045 e1039. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss C.I. The Toxicity of Poisons applied jointly. Ann. Appl. Biol. 1939 doi: 10.1111/j.1744-7348.1939.tb06990.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1744-7348.1939.tb06990.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgeling Y., et al. Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection. J. Biol. Chem. 2014;289:13&#x2013;27. doi: 10.1074/jbc.M113.469239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.469239</ArticleId><ArticleId IdType="pmc">PMC3879537</ArticleId><ArticleId IdType="pubmed">24189062</ArticleId></ArticleIdList></Reference><Reference><Citation>Canovas, B. &amp; Nebreda, A. R. Diversity and versatility of p38 kinase signalling in health and disease. Nat. Rev. Mol. Cell Biol. 22, 346-366, doi:10.1038/s41580-020-00322-w(2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7838852</ArticleId><ArticleId IdType="pubmed">33504982</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol. Med. 2020;26:97. doi: 10.1186/s10020-020-00230-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-020-00230-x</ArticleId><ArticleId IdType="pmc">PMC7594996</ArticleId><ArticleId IdType="pubmed">33121429</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., et al. Virus-induced p38 MAPK activation facilitates viral infection. Theranostics. 2020;10:12223&#x2013;12240. doi: 10.7150/thno.50992.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.50992</ArticleId><ArticleId IdType="pmc">PMC7667676</ArticleId><ArticleId IdType="pubmed">33204339</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B., et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N. Engl. J. Med. 2020;383:2291&#x2013;2293. doi: 10.1056/NEJMc2031364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031364</ArticleId><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr. Opin. Invest. Drugs. 2006;7:1020&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">17117592</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A., Gingeras T.R. Mapping RNA-seq reads with STAR. Curr Protoc Bioinformat. 2015;51:19. doi: 10.1002/0471250953.bi1114s51. 11 14 11-11 14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471250953.bi1114s51</ArticleId><ArticleId IdType="pmc">PMC4631051</ArticleId><ArticleId IdType="pubmed">26334920</ArticleId></ArticleIdList></Reference><Reference><Citation>FastQC. http://www.bioinformatics.babraham.ac.uk/projects/fastqc.</Citation></Reference><Reference><Citation>Fischer W.A., 2nd, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci. Transl. Med. 2022;14 doi: 10.1126/scitranslmed.abl7430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abl7430</ArticleId><ArticleId IdType="pmc">PMC10763622</ArticleId><ArticleId IdType="pubmed">34941423</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi, S. et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat. Commun. 13, 1547, doi:10.1038/s41467-022-29104-y(2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930970</ArticleId><ArticleId IdType="pubmed">35301314</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020;295:6785&#x2013;6797. doi: 10.1074/jbc.RA120.013679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.013679</ArticleId><ArticleId IdType="pmc">PMC7242698</ArticleId><ArticleId IdType="pubmed">32284326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D.E., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459&#x2013;468. doi: 10.1038/s41586-020-2286-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Schinazi R.F., G&#xf6;tte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 2021;297 doi: 10.1016/j.jbc.2021.100770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100770</ArticleId><ArticleId IdType="pmc">PMC8110631</ArticleId><ArticleId IdType="pubmed">33989635</ArticleId></ArticleIdList></Reference><Reference><Citation>gplots. Various R Programming tools for plotting data. github URLhttps://github.com/talgalili/gplots (2020).</Citation></Reference><Reference><Citation>Grimes J.M., Grimes K.V. p38 MAPK inhibition: a promising therapeutic approach for COVID-19. J. Mol. Cell. Cardiol. 2020;144:63&#x2013;65. doi: 10.1016/j.yjmcc.2020.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7228886</ArticleId><ArticleId IdType="pubmed">32422320</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;nl F., et al. Shooting at a moving target&#x2014;effectiveness and emerging challenges for SARS-CoV-2 vaccine development. Vaccines. 2021;9:1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8540924</ArticleId><ArticleId IdType="pubmed">34696160</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N. Engl. J. Med. 2021 doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil A.C., et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N. Engl. J. Med. 2021;384:795&#x2013;807. doi: 10.1056/NEJMoa2031994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kox M., Waalders N.J.B., Kooistra E.J., Gerretsen J., Pickkers P. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA. 2020;324:1565&#x2013;1567. doi: 10.1001/jama.2020.17052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17052</ArticleId><ArticleId IdType="pmc">PMC7489366</ArticleId><ArticleId IdType="pubmed">32880615</ArticleId></ArticleIdList></Reference><Reference><Citation>Krischuns T., et al. Phosphorylation of TRIM28 enhances the expression of IFN-beta and proinflammatory cytokines during HPAIV infection of human lung epithelial cells. Front. Immunol. 2018;9:2229. doi: 10.3389/fimmu.2018.02229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02229</ArticleId><ArticleId IdType="pmc">PMC6172303</ArticleId><ArticleId IdType="pubmed">30323812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Boehm J., Lee J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2003;2:717&#x2013;726. doi: 10.1038/nrd1177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1177</ArticleId><ArticleId IdType="pubmed">12951578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei, X. et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun. 11, 3810, doi:10.1038/s41467-020-17665-9(2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>LeMessurier K.S., Hacker H., Chi L., Tuomanen E., Redecke V. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog. 2013;9 doi: 10.1371/journal.ppat.1003727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003727</ArticleId><ArticleId IdType="pmc">PMC3820719</ArticleId><ArticleId IdType="pubmed">24244159</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y., Smyth G.K., Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47:e47. doi: 10.1093/nar/gkz114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz114</ArticleId><ArticleId IdType="pmc">PMC6486549</ArticleId><ArticleId IdType="pubmed">30783653</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463&#x2013;469. doi: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNee W., Allan R.J., Jones I., De Salvo M.C., Tan L.F. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax. 2013;68:738&#x2013;745. doi: 10.1136/thoraxjnl-2012-202744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2012-202744</ArticleId><ArticleId IdType="pubmed">23539534</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B.B., et al. Type I interferon promotes alveolar epithelial type II cell survival during pulmonary Streptococcus pneumoniae infection and sterile lung injury in mice. Eur. J. Immunol. 2016;46:2175&#x2013;2186. doi: 10.1002/eji.201546201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201546201</ArticleId><ArticleId IdType="pmc">PMC5370074</ArticleId><ArticleId IdType="pubmed">27312374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso G., et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 2007;178:3126&#x2013;3133. doi: 10.4049/jimmunol.178.5.3126.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.5.3126</ArticleId><ArticleId IdType="pubmed">17312160</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinot M., et al. Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019. Clin. Infect. Dis. 2020;73:e1762&#x2013;e1765. doi: 10.1093/cid/ciaa1474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1474</ArticleId><ArticleId IdType="pmc">PMC7543308</ArticleId><ArticleId IdType="pubmed">32986807</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani T., Fukushi S., Saijo M., Kurane I., Morikawa S. Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cells. Biochem. Biophys. Res. Commun. 2004;319:1228&#x2013;1234. doi: 10.1016/j.bbrc.2004.05.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.05.107</ArticleId><ArticleId IdType="pmc">PMC7111015</ArticleId><ArticleId IdType="pubmed">15194498</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473&#x2013;474. doi: 10.1126/science.abb8925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8925</ArticleId><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601-615, doi:10.1038/s41591-021-01283-z(2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh S.J., Shin O.S. SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways. J. Microbiol. 2022 doi: 10.1007/s12275-022-1525-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12275-022-1525-1</ArticleId><ArticleId IdType="pmc">PMC8817151</ArticleId><ArticleId IdType="pubmed">35122601</ArticleId></ArticleIdList></Reference><Reference><Citation>Prelli Bozzo, C. et al. IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. Nat. Commun. 12, 4584, doi:10.1038/s41467-021-24817-y(2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319209</ArticleId><ArticleId IdType="pubmed">34321474</ArticleId></ArticleIdList></Reference><Reference><Citation>R_Core_Team. (2013).</Citation></Reference><Reference><Citation>R_Core_Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria URL http://www.R-project.org/(2014).</Citation></Reference><Reference><Citation>Repurposed W.H.O. Antiviral drugs for covid-19 &#x2014; interim WHO solidarity trial results. N. Engl. J. Med. 2020;384:497&#x2013;511. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M.E., et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovas, A. et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis 24, 145-157, doi:10.1007/s10456-020-09753-7(2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556767</ArticleId><ArticleId IdType="pubmed">33058027</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi G., et al. Opposing activities of IFITM proteins in SARS-CoV-2 infection. EMBO J. 2021;40 doi: 10.15252/embj.2020106501.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106501</ArticleId><ArticleId IdType="pmc">PMC7744865</ArticleId><ArticleId IdType="pubmed">33270927</ArticleId></ArticleIdList></Reference><Reference><Citation>Stackaruk M.L., Lee A.J., Ashkar A.A. Type I interferon regulation of natural killer cell function in primary and secondary infections. Expert Rev. Vaccines. 2013;12:875&#x2013;884. doi: 10.1586/14760584.2013.814871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2013.814871</ArticleId><ArticleId IdType="pubmed">23984959</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimgalore. https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/.</Citation></Reference><Reference><Citation>Williamson E.J., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430&#x2013;436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav B., Wennerberg K., Aittokallio T., Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 2015;13:504&#x2013;513. doi: 10.1016/j.csbj.2015.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2015.09.001</ArticleId><ArticleId IdType="pmc">PMC4759128</ArticleId><ArticleId IdType="pubmed">26949479</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, S. et al. A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. Nat. Med. 27, 659-667, doi:10.1038/s41591-021-01281-1(2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33633408</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>